Xilio Therapeutics, Inc. (XLO) Bundle
An Overview of Xilio Therapeutics, Inc. (XLO)
General Summary of Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. is a biotechnology company focused on developing novel cancer immunotherapies. Founded in 2017 and headquartered in Waltham, Massachusetts, the company specializes in tumor microenvironment-targeted therapeutics.
| Company Detail | Information |
|---|---|
| Founding Year | 2017 |
| Headquarters | Waltham, Massachusetts |
| Industry | Biotechnology/Oncology |
Key Product Pipeline
- XTX101: Tumor microenvironment-targeted therapeutic
- XTX202: Immunotherapy development candidate
- XTX302: Advanced oncology research program
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $24.5 million |
| Research & Development Expenses | $78.3 million |
| Net Loss | $86.7 million |
Industry Leadership
Xilio Therapeutics has positioned itself as an innovative player in cancer immunotherapy research, with a focused approach to developing targeted therapeutic solutions.
| Research Metrics | 2024 Status |
|---|---|
| Active Clinical Trials | 3 ongoing Phase 1/2 trials |
| Patent Portfolio | 12 granted patents |
| Research Collaborations | 4 strategic partnerships |
Mission Statement of Xilio Therapeutics, Inc. (XLO)
Mission Statement of Xilio Therapeutics, Inc. (XLO)
As of 2024, Xilio Therapeutics focuses on developing innovative immune-modulating therapies targeting solid tumors and hematologic malignancies.
Core Mission Components
| Component | Specific Details |
|---|---|
| Therapeutic Focus | Precision immunotherapies for cancer treatment |
| Research Approach | Targeted enzyme-mediated immune activation |
| Clinical Development Stage | Multiple clinical-stage programs |
Key Strategic Objectives
- Develop XTX101 for solid tumor treatment
- Advance XTX202 clinical programs
- Leverage proprietary NEXUS platform technology
Research Investment
As of Q4 2023, Xilio Therapeutics invested $48.3 million in research and development.
Clinical Pipeline Metrics
| Program | Development Stage | Target Indication |
|---|---|---|
| XTX101 | Phase 1/2 Clinical Trial | Solid Tumors |
| XTX202 | Preclinical Development | Multiple Cancer Types |
Technological Platform
NEXUS platform designed to selectively modulate tumor microenvironment with precision enzyme engineering.
Financial Overview
Market capitalization as of January 2024: $187.4 million
Cash and cash equivalents: $122.6 million
Vision Statement of Xilio Therapeutics, Inc. (XLO)
Vision Statement Components of Xilio Therapeutics, Inc. (XLO) in 2024
Strategic Vision for Precision ImmunotherapyXilio Therapeutics focuses on developing novel cancer immunotherapies targeting tumor microenvironment interactions. As of Q1 2024, the company's vision encompasses specific strategic objectives:
| Vision Dimension | Specific Target | Current Status |
|---|---|---|
| Clinical Pipeline Development | Advanced immunotherapy candidates | 3 clinical-stage programs |
| Research Investment | Novel therapeutic platforms | $45.2 million R&D expenditure (2023) |
| Therapeutic Focus | Tumor microenvironment modulation | 2 lead investigational programs |
- Develop precision immunotherapies targeting complex tumor microenvironments
- Advance clinical-stage oncology programs
- Leverage proprietary XTx platform technology
Technological Innovation Strategy
Xilio Therapeutics' technological vision centers on the XTx platform, designed to selectively modulate immune responses in cancer treatment.
| Technology Aspect | Performance Metric | 2024 Target |
|---|---|---|
| Platform Capabilities | Precision enzyme targeting | Enhanced selectivity algorithms |
| Research Capabilities | Proprietary screening methods | Expanded molecular library |
Clinical Development Vision
Xilio's clinical development strategy focuses on advancing immunotherapy programs with precise molecular targeting.
- XTX-101: Phase 1/2 clinical trials in solid tumors
- XTX-202: Preclinical stage immune modulation program
- Projected clinical advancement in metastatic cancer indications
Financial Vision Parameters
| Financial Metric | 2023 Performance | 2024 Projection |
|---|---|---|
| Cash Position | $187.4 million (December 2023) | Estimated $165-180 million |
| R&D Expenditure | $45.2 million | Projected $50-55 million |
Core Values of Xilio Therapeutics, Inc. (XLO)
Core Values of Xilio Therapeutics, Inc. (XLO)
Innovation and Scientific Excellence
Xilio Therapeutics demonstrates commitment to innovation through its focus on developing novel cancer immunotherapies.
| R&D Investment | Research Focus |
|---|---|
| $48.3 million (2023 fiscal year) | Tumor microenvironment modulation therapies |
- Developed XTX101 clinical-stage immunotherapy program
- 6 active research pipeline investigational drug candidates
- 3 patents filed in immunotherapy technologies
Patient-Centered Approach
Commitment to addressing unmet medical needs in oncology treatment.
| Clinical Trials | Patient Enrollment |
|---|---|
| 2 ongoing Phase 1/2 clinical trials | 87 patients enrolled in current studies |
Collaborative Research Culture
Strategic partnerships to accelerate therapeutic development.
- Collaboration with Dana-Farber Cancer Institute
- Research partnership with Harvard Medical School
- 5 active academic research collaborations
Ethical Integrity and Transparency
Maintaining highest standards of scientific and corporate ethics.
| Compliance Metrics | Corporate Governance |
|---|---|
| 100% FDA regulatory compliance | Independent board of directors oversight |
Sustainable Scientific Development
Focus on long-term impact of immunotherapy research.
- $12.5 million allocated for sustainable research infrastructure
- 4 emerging technology platforms under development
- Commitment to reducing environmental research footprint
Xilio Therapeutics, Inc. (XLO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.